Mesoblast (MESO) announced its addition to the S&P Dow Jones Indices’ S&P/ASX 200 Index effective March 6, 2025 on the Australian Stock Exchange.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MESO:
- Mesoblast’s Earnings Call: RYONCIL Approval & Growth
- Buy Rating for Mesoblast Driven by Promising Market Position and Strong Financial Backing
- Mesoblast Reports FDA Approval and Financial Results
- Mesoblast Appoints Dr. Gregory George to Board, Enhancing Strategic and Operational Expertise
- Mesoblast price target raised to $24 from $15 at Piper Sandler